Skip to main
DFTX

DFTX Stock Forecast & Price Target

DFTX Analyst Ratings

Based on 13 analyst ratings
Buy
Strong Buy 46%
Buy 54%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Definium Therapeutics is well positioned for long-term success with their innovative next-generation therapeutics intended to address the underlying causes of psychiatric and neurological disorders, and their lead candidate, DT120 ODT, having received FDA Breakthrough Therapy Designation for GAD. The recent strong Phase 3 data for DT120 in MDD and the upcoming Phase 3 data for GAD, along with a diversified pipeline and potential for M&A activity in the space, make Definium a compelling investment opportunity with potential for further upside.

Bears say

Definium Therapeutics is facing risks in their late-stage pipeline of four Phase 3 trials for GAD and MDD, as well as potential operational challenges as they prepare for the launch of DT120 ODT. This, combined with a recent offering and additional share count, leads to a downward revision in our DCF-based price target from $60 to $58. While the company's probability of approval for their drugs is promising, their conservative launch timing and price assumptions may impact their potential peak sales of $3.8bn/3.4bn for MDD/GAD in 2037E.

DFTX has been analyzed by 13 analysts, with a consensus rating of Buy. 46% of analysts recommend a Strong Buy, 54% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Definium Therapeutics Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Definium Therapeutics Inc (DFTX) Forecast

Analysts have given DFTX a Buy based on their latest research and market trends.

According to 13 analysts, DFTX has a Buy consensus rating as of Aug 8, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $55, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $55, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Definium Therapeutics Inc (DFTX)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.